“Our RAS-targeting franchise continues to advance rapidly, with multiple important clinical milestones approaching,” said Jonathan Lim, Erasca’s (ERAS) chairman, CEO, and co-founder. “A U.S. patent was issued that covers the composition of matter for our potential best-in-class pan-RAS molecular glue ERAS-0015, the first of several patents we anticipate may be issued, which would strengthen the intellectual property surrounding our differentiated RAS portfolio. We also reinforced our scientific leadership with the promotion of Robert Shoemaker, Ph.D., to chief scientific officer. As a core member of Erasca’s founding team, Robert has been instrumental in shaping our research strategy since company inception.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca price target raised to $6 from $4 at Stifel
- Erasca announces issuance of U.S. patent covering ERAS-0015
- Erasca, Inc. Advances with Promising Phase 1 Study on ERAS-4001
- Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study
- Erasca’s SEACRAFT-2 Study: A Promising Step in Melanoma Treatment